The results showed that the median concentration of TBARS in plasma of patients with RA decreased by 12% 3 months after starting anti-TNF-α therapy (from 0.098 to 0.080 μmol/g, F = 8.9, p = 0.41). This evidence concerns the gene TNF and rheumatoid arthritis.